Q-omics provides the consensus-scored MYF5 profile across patient tissues and cancer cell-line models. MYF5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MYF5 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MYF5 RNA expression shows 5,804 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and KIRC as cancer lineages where MYF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYF5 survival associations across molecular data types. MYF5 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYF5 RNA expression–survival associations across cancer types. High MYF5 expression shows unfavorable associations in STAD, LIHC, THCA, KIRP and MESO, but favorable associations in UCS. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for MYF5 RNA expression.
This table summarizes MYF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYF5 shows lower tumor expression in KIRC, KIRP and PAAD. The KIRC box plot shows higher MYF5 RNA expression in normal versus tumor tissue (log2 FC = −0.048, t-test p < 0.001).
This table shows molecular features associated with MYF5 in patient tissues and cancer cell lines. In patient samples, MYF5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MYF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
